Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRRT Plus CAPTEM vs CAPTEM Alone in Well-Differentiated GEP-NETs
NCT07910760Phase 3Not yet recruiting
- Sponsor
- Tata Memorial Hospital
- Start
- Oct 2026
- Primary completion
- Oct 2031
01
Overview
A Phase 3 trial of lutetium Lu 177 dotatate in gastroenteropancreatic neuroendocrine tumor (GEP-NET), sponsored by Tata Memorial Hospital. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT07910760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07910760.